title: Assessment of proliferation index with MIB-1 as a prognostic factor in radiation therapy for cervical cancer.
abstract: OBJECTIVE
  The relationship between the expression of murine monoclonal antibody MIB-1, which reacts with Ki-67 nuclear antigen, a marker for proliferating cells, and the prognosis of stage IIIb cervical cancer after radiation therapy was analyzed.
  
  
  METHODS
  A total of 67 patients with stage IIIb cervical cancer who had received radiation therapy were included in the retrospective study. The labeled streptavidin-biotin method was used for immunohistochemical staining of the MIB-1 protein.
  
  
  RESULTS
  In 32 patients showing a high MIB-1 index (percentage of cells labeled with MIB-1 >/=26.4%), the cumulative 5- and 8-year survival rates were 75.8 and 61.5%, respectively, significantly better (P < 0.05) than those in 35 patients with a low MIB-1 index (<26.4%) (59.6 and 41.1%, respectively). Serum squamous cell carcinoma antigen levels, an index of the response to radiation therapy, decreased to </=2.0 ng/mL in 100 and 68% of patients in the high and low MIB-1 index groups, respectively (P < 0.05).
  
  
  CONCLUSIONS
  These results indicate that MIB-1 antigen may be effective in predicting the sensitivity of cervical cancer to radiation therapy and stage IIIb cervical cancer prognosis.
authors.affiliation: Department of Obstetrics and Gynecology, Jichi Medical School, 3311 Yakushiji, Minamikawachi, Kawachi, Tochigi, 329-0498, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Suzuki
authors.forename: S
authors.initials: S
authors.lastname: Tsukagoshi
authors.forename: Y
authors.initials: Y
authors.lastname: Saga
authors.forename: M
authors.initials: M
authors.lastname: Ohwada
authors.forename: I
authors.initials: I
authors.lastname: Sato
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000276:immunology; D000951:Antigens, Neoplasm / Q000097:blood; D034961:Antigens, Nuclear; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000096:biosynthesis* / Q000097:blood / Q000276:immunology; D002455:Cell Division / Q000276:immunology; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000276:immunology; D008875:Middle Aged; D009687:Nuclear Proteins / Q000096:biosynthesis* / Q000276:immunology; D011379:Prognosis; D012189:Retrospective Studies; D015843:Serpins; D016019:Survival Analysis; D002583:Uterine Cervical Neoplasms / Q000276:immunology* / Q000473:pathology / Q000532:radiotherapy*
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D034961:Antigens, Nuclear; D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D009687:Nuclear Proteins; D015843:Serpins; C051072:squamous cell carcinoma-related antigen